Early treatment with the experimental oral therapy vidofludimus calcium (IMU-838) may lead to less long-term disability in people with progressive forms of multiple sclerosis (MS), according to new data from the CALLIPER Phase 2 trial and its extension. Immunic, the company developing vidofludimus calcium, presented the findings…
Discussion
Genentech’s experimental oral therapy fenebrutinib may help control the chronic inflammation in the brain associated with disability progression in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from three ongoing Phase 3 trials, in which…
Discussion
About four out of 10 people with multiple sclerosis (MS) in Thailand were found to be either at risk of malnutrition or already malnourished, which appear to be associated with more severe disability, a single-center study shows. Data also showed that a significant proportion of people with two related…
Discussion
When Christina Applegate was diagnosed with multiple sclerosis (MS) in 2021, she finally had an explanation for the symptoms that had been disrupting her life. The diagnosis also gave her a community where she could share her experiences, find support, and help others facing the same challenges. Now,…
Discussion
In people with multiple sclerosis (MS), pain is associated with more reported difficulties with thinking and memory, but does not predict how patients perform in objective cognition tests, according to a recent study. Mental health issues, along with pain and fatigue, were associated with greater perceived cognitive problems. “Given…
Get regular updates to your inbox.
